T-group (topology)
1.1.5 FMN-binding split barrel
Ligands and drugs
10,024
Member domains
5,376
with ligand contacts (≤ 4 Å)
53.6% of members
3,199
with DrugDomain annotations
31.9% of members
1,899
with a DrugBank compound
18.9% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 1.1.5 belongs to X-group 1 cradle loop barrel, which binds 9.4 ligand superclasses per 20 proteins, broader than 87% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03247 | FMN | Flavin mononucleotide | 139 |
| DB03147 | FAD | Flavin adenine dinucleotide | 83 |
| DB03913 | F42 | Coenzyme F420 | 31 |
| DB18834 | 7YY | Ensitrelvir | 31 |
| DB11575 | SUE | Grazoprevir | 19 |
| DB14128 | NAD | Nadide | 17 |
| DB03345 | BME | Mercaptoethanol | 14 |
| DB18267 | HEM | Ferroheme | 14 |
| DB00141 | NAG | N-Acetylglucosamine | 12 |
| DB00114 | PLP | Pyridoxal phosphate | 10 |
| DB00135 | TYR | Tyrosine | 10 |
| DB13879 | O31 | Glecaprevir | 10 |
| DB00125 | ARG | Arginine | 8 |
| DB03793 | BEZ | Benzoic acid | 8 |
| DB06841 | 0G6 | [(2R)-1-[(2S)-2-[[(2S,3S)-1-Chloro-6-(diaminomethylideneamino)-2-hydroxyhexan-3-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]azanium | 7 |
| DB00128 | ASP | Aspartic acid | 6 |
| DB01972 | 5GP | Guanosine-5'-Monophosphate | 6 |
| DB11929 | SU3 | Vaniprevir | 6 |
| DB16514 | 80I | Lufotrelvir | 6 |
| DB02313 | AG7 | Ethyl (4R)-4-{[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-4-oxoheptanoyl]amino}-5-[(3S)-2-oxo-3-pyrrolidinyl]pentanoate | 5 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 1,005 |
| CL | CHLORIDE ION | 444 |
| FMN | FLAVIN MONONUCLEOTIDE | 142 |
| NAmetal | SODIUM ION | 139 |
| 4WI | (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide | 121 |
| Kmetal | POTASSIUM ION | 117 |
| MNmetal | MANGANESE (II) ION | 102 |
| FAD | FLAVIN-ADENINE DINUCLEOTIDE | 95 |
| V2M | N-[(2S)-1-({(2S,3S)-3,4-dihydroxy-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl}amino)-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide | 73 |
| HEM | PROTOPORPHYRIN IX CONTAINING FE | 56 |
| 7YY | 6-[(6-chloranyl-2-methyl-indazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[[2,4,5-tris(fluoranyl)phenyl]methyl]-1,3,5-triazine-2,4-dione | 55 |
| 4LU | 1-deoxy-5-O-phosphono-1-(3,3,4,5-tetramethyl-9,11-dioxo-2,3,8,9,10,11-hexahydro-7H-quinolino[1,8-fg]pteridin-12-ium-7-yl)-D-ribitol | 50 |
| UED | N~2~-[(benzyloxy)carbonyl]-N-{(2S)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide | 50 |
| CAmetal | CALCIUM ION | 45 |
| K36 | (1S,2S)-2-({N-[(benzyloxy)carbonyl]-L-leucyl}amino)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonic acid | 45 |
| C2E | 9,9'-[(2R,3R,3aS,5S,7aR,9R,10R,10aS,12S,14aR)-3,5,10,12-tetrahydroxy-5,12-dioxidooctahydro-2H,7H-difuro[3,2-d:3',2'-j][1,3,7,9,2,8]tetraoxadiphosphacyclododecine-2,9-diyl]bis(2-amino-1,9-dihydro-6H-purin-6-one) | 39 |
| BYN | hydroxylated prenyl-FMN | 37 |
| X77 | N-(4-tert-butylphenyl)-N-[(1R)-2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-1H-imidazole-4-carboxamide | 37 |
| 80I | [(3~{S})-3-[[(2~{S})-2-[(4-methoxy-1~{H}-indol-2-yl)carbonylamino]-4-methyl-pentanoyl]amino]-2-oxidanylidene-4-[(3~{R})-2-oxidanylidene-3,4-dihydropyrrol-3-yl]butyl] dihydrogen phosphate | 32 |
| FHR | ~{N}-[(2~{S})-3-cyclohexyl-1-oxidanylidene-1-[[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]amino]propan-2-yl]-1~{H}-indole-2-carboxamide | 32 |